share_log

SciSparc | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  Feb 29 22:08
Summary by Futu AI
SciSparc Ltd., a clinical-stage pharmaceutical company, announced on February 29, 2024, the successful delivery of its SCI-210 treatment for a clinical trial targeting Autism Spectrum Disorder (ASD) in pediatric patients. The trial, to be conducted at the Soroka Medical Center, will test the safety, tolerability, and efficacy of SCI-210 compared to CBD monotherapy. SCI-210 is a proprietary combination of cannabidiol-rich oil and CannAmide, SciSparc's palmitoylethanolamide-based tablets. The randomized, double-blind, placebo-controlled trial with cross-over will span 20 weeks and enroll 60 children. Primary efficacy endpoints include the Aberrant Behavior Checklist-Community, the Clinical Global Impressions-Improvement scale, and determining the effective therapeutic dosage. SciSparc's CEO, Oz Adler, expressed confidence in the treatment's potential to offer a more effective and safe option for patients. The company aims to proceed with the commercialization of SCI-210 in Israel following the trial's outcome. The press release also serves as a forward-looking statement and is incorporated by reference into the company's registration statements filed with the SEC.
SciSparc Ltd., a clinical-stage pharmaceutical company, announced on February 29, 2024, the successful delivery of its SCI-210 treatment for a clinical trial targeting Autism Spectrum Disorder (ASD) in pediatric patients. The trial, to be conducted at the Soroka Medical Center, will test the safety, tolerability, and efficacy of SCI-210 compared to CBD monotherapy. SCI-210 is a proprietary combination of cannabidiol-rich oil and CannAmide, SciSparc's palmitoylethanolamide-based tablets. The randomized, double-blind, placebo-controlled trial with cross-over will span 20 weeks and enroll 60 children. Primary efficacy endpoints include the Aberrant Behavior Checklist-Community, the Clinical Global Impressions-Improvement scale, and determining the effective therapeutic dosage. SciSparc's CEO, Oz Adler, expressed confidence in the treatment's potential to offer a more effective and safe option for patients. The company aims to proceed with the commercialization of SCI-210 in Israel following the trial's outcome. The press release also serves as a forward-looking statement and is incorporated by reference into the company's registration statements filed with the SEC.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.